Trial results comparing liraglutide to semaglutide for body weight management in adults with overweight or obesity were published on 2022-01-01 in JAMA. The STEP 8 study investigated the efficacy of weekly subcutaneous semaglutide versus daily liraglutide in this population.
Background
Liraglutide is a medication known by various aliases including Saxenda and Victoza, and is also formulated with insulin degludec as Xultophy 100/3.6. Semaglutide is another medication, known by brand names such as Ozempic and Wegovy. Both drugs are used in the context of weight management. This particular study focused on their comparative effect on body weight in adults classified as overweight or obese, specifically excluding individuals with diabetes.
Trial design
The STEP 8 study was a randomized clinical trial designed to investigate the comparative effect of two different dosing regimens: weekly subcutaneous semaglutide versus daily liraglutide. The trial's objective was to assess changes in body weight in adults who presented with overweight or obesity and did not have a diagnosis of diabetes.
What this means
The publication of the STEP 8 study provides important comparative data for clinicians and researchers considering treatment options for chronic weight management. This research offers insights into the relative efficacy of weekly semaglutide compared to daily liraglutide in a specific population of adults with overweight or obesity who do not have diabetes, contributing to evidence-based decision-making in this field.
Source
The information for this article is based on a research publication from PubMed. The study, titled "Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clini", was published on 2022-01-01 and is accessible via pubmed.ncbi.nlm.nih.gov.